In a news release, Avivagen Inc. (VIV:TSX.V; VIVXF:OTCQB) announced that the benefits of its OxC-beta product for broiler poultry will be highlighted in a paper to be published in an upcoming Poultry Science issue. The company noted that Poultry Science is an internationally known, peer-reviewed journal.
"This publication provides an additional level of scientific validation supporting the commercially meaningful benefits of using OxC-beta for broiler poultry, providing additional value to Avivagen's current and future customers committed to eliminating or reducing antibiotic use in their operations," Avivagen CEO Kym Anthony said in the release.
Titled "Effect of Oxidized β-Carotene (OxBC) on the Growth and Feed Efficiency of Broilers," the article will report the positive results of two studies in which the diet of broiler poultry was supplemented with OxC-beta.
The first trial was done in Ontario, Canada, the second in Scotland. In both, birds were raised in typical commercial environments relative to the locale.
When compared to birds in control groups, the birds that received OxC-beta showed significantly better growth performance as measured by average daily weight gain, efficiency in using feed and other metrics.
"These findings demonstrate that dietary supplementation with OxC-beta helps broiler poultry achieve their full growth potential under real world commercial conditions without the use of antibiotics," the release noted.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.
